Drug intelligence / Profile preview

KM114

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

KM114 is a monoclonal antibody targeting CD44, developed as a potential therapy for immune thrombocytopenia (ITP). In murine models of ITP, KM114 successfully ameliorated the condition, demonstrating efficacy at significantly lower dosages compared to intravenous immunoglobulin (IVIg). Its mechanism of action involves the inhibitory IgG receptor FcγRIIB, which is required for its therapeutic function, similar to IVIg. However, unlike IVIg, the Fc portion of the CD44 antibody is not essential for its ameliorative effects. KM114 is being explored as a very-low-dose recombinant therapeutic option for human ITP.

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on KM114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KM114.

Explore the full profile